BPC-157 is a local repair peptide — it drives angiogenesis and growth-factor signaling at the injury site through VEGFR2 / Akt / eNOS and Src-Caveolin-1. Best for tendon, ligament, joint, and gut lesions where you want to concentrate healing in a specific tissue.
TB-500 (Thymosin β-4) is a systemic cell-migration peptide — it sequesters G-actin and regulates actin polymerization, driving the fibroblast/endothelial/stem-cell migration phase of wound repair. Best for diffuse damage, older injuries, and cardiac or neural contexts.
GHK-Cu is a tissue-remodeling peptide — a copper-binding tripeptide that modulates expression of roughly 4,000 human genes toward a younger, repair-oriented profile. Best for skin, collagen turnover, hair, and long-horizon anti-inflammaging.
The three are mechanistically complementary, which is why they're routinely stacked (Wolverine = BPC-157 + TB-500; GLOW = GHK-Cu + BPC-157 + TB-500). They can be reconstituted into a single vial and drawn in one syringe.
The clearest way to hold these three apart is by where their biology happens. BPC-157 is local and pathway-specific. TB-500 is systemic and structural. GHK-Cu is transcriptional and long-horizon.
| Domain | BPC-157 | TB-500 (Tβ4) | GHK-Cu |
|---|---|---|---|
| Primary target | VEGFR2 / Akt / eNOS; Src-Caveolin-1; FAK-paxillin | G-actin sequestration; actin polymerisation dynamics | Copper chaperone → broad transcriptional modulation |
| Where it works | Locally at/near injection — concentrates growth-factor signalling at the lesion | Systemically — raises migratory capacity of fibroblasts, endothelial cells, progenitor cells everywhere | Skin ECM and broadly: collagen, elastin, glycosaminoglycan, DNA-repair, antioxidant and anti-inflammatory genes |
| Time course | Days to weeks — acute repair window | Days to weeks systemically; corneal healing within 2–7 days | Weeks to months — gene-expression reprogramming plays out over cycles |
| Angiogenesis | Upregulates VEGFR2; promotes endothelial tube formation | Recruits endothelial cells and promotes vascular cell migration | Promotes vascularization in wound beds via VEGF/angiogenic gene induction |
| Inflammation | Dampens TNF-α, IL-6 in rodent injury and colitis models | Suppresses NF-κB-driven inflammation, reduces inflammatory cell infiltration | Reduces TNF-α, IL-6; GHK downregulates pro-inflammatory gene clusters |
| Collagen/ECM | Indirect — enhances fibroblast activity at the site | Indirect — provides migratory substrate; modulates matrix metalloproteinases | Direct — stimulates collagen I, elastin, decorin, glycosaminoglycan synthesis |
This is why they aren't competing tools. BPC-157 focuses repair at the injury. TB-500 brings in the cells that do the work. GHK-Cu rewires the transcriptional environment the repair is happening in.
The three have very different evidence stacks. A candid read:
Use this as a starting-point heuristic — not a prescription. Real protocols are individualized and should involve a licensed clinician.
| If your goal is... | Lean toward | Why |
|---|---|---|
| Tendon / ligament / joint injury, single site | BPC-157 | Local angiogenic / growth-factor concentration at the lesion; inject near the site |
| Chronic or diffuse soft-tissue damage | TB-500 | Systemic cell migration reaches everywhere at once |
| Older, stalled injuries that plateaued | TB-500 (± BPC-157) | Stalled healing is usually a migration/remodeling problem more than a signaling problem |
| Post-operative or post-procedure recovery | BPC-157 + TB-500 | Acute repair window benefits from both pathways simultaneously |
| Skin rejuvenation, collagen, photoageing | GHK-Cu (topical + SubQ) | Direct ECM gene modulation; established dermal evidence |
| Hair density and scalp health | GHK-Cu (± AHK-Cu topically) | Dermal-papilla gene signature and follicle size effects in studies |
| Gut / IBD symptoms | BPC-157 | Gut-protective mechanism is its best-characterized in-human application |
| Cardiac or neural recovery research | TB-500 | Cardiac progenitor mobilisation and CNS neuroprotection signals |
| Global anti-inflammaging / longevity framing | GHK-Cu | Broad transcriptional reprogramming toward younger expression patterns |
Concrete scenarios where one compound or combination fits more naturally than another. These are illustrative only — real protocols should be individualized with a licensed clinician, and none of these compounds is FDA-approved for the indications below.
Lean toward: BPC-157 alone, or BPC-157 + TB-500 (Wolverine Stack) when the injury is severe or associated with adjacent muscle damage. BPC-157's VEGFR2 / Akt / eNOS and Src-Caveolin-1 signalling concentrates the angiogenic response at the injury site when injected near the lesion, which is the window where local growth-factor recruitment matters most. TB-500 layers on systemic fibroblast, endothelial, and progenitor-cell migratory capacity so the angiogenic gradient has cells to act on. GHK-Cu has a smaller role in the first 2 weeks post-injury but can be added from week 2–3 onward if the downstream ECM remodeling quality is a priority (e.g., deep muscle tear, contusion, high-grade sprain).
Lean toward: TB-500 primary with BPC-157 as booster, then a GHK-Cu remodeling cycle. Chronic tendinopathy is typically a failure of the migratory/remodeling phase rather than the initial signalling phase — the classic angiogenic cascade has already fired, failed to produce durable tissue, and left a stalled repair. TB-500's G-actin sequestration and generalised pro-migratory effect gives that stalled tissue a different tool. Many community protocols run a 4–6 week TB-500 load plus daily BPC-157, then step into a 4–8 week GHK-Cu cycle targeted at the matrix quality of the new repair. Eccentric loading rehab alongside is standard.
Lean toward: Full three-way GLOW Stack starting once the surgical team clears peptide use. The acute post-op repair window is the single case where all three layers operate at peak usefulness simultaneously — signalling (BPC-157), migration (TB-500), and transcriptional remodeling (GHK-Cu). Community protocols typically run the stack 6–8 weeks post-op, then taper based on functional return. Important practical note: some surgeons specifically object to pro-angiogenic and pro-migratory compounds in the immediate peri-operative window because of theoretical bleeding, graft-take, or incision-tension concerns — always clear timing with the surgical team.
Lean toward: GHK-Cu primary — topical daily plus 1–2 mg SubQ several times per week. The matrix-remodeling and transcriptional layer is the compound's entire point, and the dermal evidence base specifically supports this use case. BPC-157 can be added at a lower daily SubQ dose when the goal includes gut-lining support or generalised tissue maintenance, and TB-500 is usually not needed unless there is a diffuse connective-tissue concern. This is the scenario where the GLOW Stack overlaps most with cosmetic-grade peptide regimens, and also the scenario where topical-only GHK-Cu (no injections) is a reasonable entry point before any SubQ use is considered.
Community ranges drawn from the available literature and practitioner reports — not from an approved label. Always confirm with a licensed clinician and cross-check with the full profiles: BPC-157, TB-500, GHK-Cu.
| Parameter | BPC-157 | TB-500 | GHK-Cu |
|---|---|---|---|
| Typical dose (SubQ) | 250–500 mcg, 1–2×/day | 2–5 mg/week, split 1–2×/week | 1–2 mg/day (injectable); 1–3% topical |
| Loading phase | Usually none — start at maintenance | 5–10 mg/week × 4–6 weeks, then taper | Not common — steady cadence preferred |
| Cycle length | 4–8 weeks on, 2–4 off | 4–6 weeks on, 2–4 off | 4–8 weeks on, 1–2 off |
| Injection site | Near injury when possible | Any SubQ; systemic effect | Any SubQ; topical to treatment area |
| Typical vial | 5 mg or 10 mg lyophilized | 5 mg or 10 mg lyophilized | 50 mg lyophilized (injectable); creams/serums at 1–3% |
| Reconstitution | 2 mL BAC water → 2,500/5,000 mcg/mL | 2 mL BAC water → 2.5/5 mg/mL | 5 mL BAC water → 10 mg/mL |
→ Open the Kalios Dosing Calculator to translate any of the above into exact syringe units.
These ranges reflect what the literature and community practice describe — not FDA-approved dosing. None of these three compounds has an approved label for general tissue repair. Individual protocols should involve a licensed clinician.
The three-way stack is popular precisely because the mechanisms don't overlap. You aren't stacking three drugs that do the same thing harder — you're covering three distinct layers of the repair cascade:
This is the logic behind the two most popular pre-mixed stacks:
The two-way tissue-repair pairing. Adds migration (TB-500) to local signaling (BPC-157). Typically delivered as a 5/5 mg or 10/10 mg dual vial. Best studied community protocol for acute musculoskeletal injury.
The three-way stack: adds GHK-Cu's remodeling layer on top of Wolverine. Typical ratio is 5:1:1 (50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500). Skin, collagen, and general anti-inflammaging extend beyond pure injury-recovery use cases.
Why the mechanisms chain together. The three-way logic is not just additive — the biology dovetails. BPC-157's VEGFR2 / Akt / eNOS axis establishes a localised angiogenic gradient, which is what endothelial cells and pericytes migrate toward. TB-500's G-actin sequestration is precisely the cellular machinery that governs actin polymerization dynamics during that migration — without ordered G-actin → F-actin transition, fibroblasts and endothelial progenitors cannot move along the BPC-driven gradient. Once those cells arrive and begin depositing matrix, GHK-Cu's transcriptional effect shapes what gets laid down: collagen I over disorganised collagen III, organised elastin, appropriate glycosaminoglycans, and a less inflammatory cytokine milieu. Removing any single layer leaves a recognisable gap in the cascade — signalling without migration produces blood flow into tissue that still can't rebuild; migration without remodeling produces cellularity without durable matrix; remodeling without signalling produces a transcriptional environment without any injury-triggered program to modulate.
Time-scale complementarity. Each layer also acts on a different clock. BPC-157's effects on local blood flow, pain, and early granulation tissue are measurable within days. TB-500's migratory-phase contribution accumulates over the first 2–6 weeks — this is why community protocols typically front-load a 4–6 week TB-500 block in acute injury. GHK-Cu's gene-expression shift is intentionally slower, playing out over weeks to months, which is why its strongest evidence base (dermal photodamage, post-procedure recovery, hair density) is in indications with long measurement horizons. Using all three together is effectively running three repair programs in parallel at their natural tempos — not stacking three doses of the same pathway.
Yes. All three are small water-soluble peptides without known pairwise interactions in solution, and they are already sold pre-mixed as the GLOW and KLOW stacks. Two practical notes:
The colour of a combined vial reconstituted with GHK-Cu will be pale blue from the copper complex — that is normal and expected, not contamination.
Each has a distinct safety profile. Most reports are from animal models and community use rather than large clinical trials.
| Concern | BPC-157 | TB-500 | GHK-Cu |
|---|---|---|---|
| Common AEs | GI (nausea, bloating), injection-site reactions, headache | Lethargy, mild flu-like symptoms during initial loading, injection-site reactions | Injection-site reactions, rare blue skin discolouration at higher doses (copper-related) |
| Serious concerns | Theoretical tumor-promotion via angiogenesis (unproven but flagged by Józwiak 2025, McGuire 2025); growth-factor concerns | Same pro-migration / pro-angiogenic signal raises theoretical cancer concerns in active or precancerous disease | Copper accumulation at high chronic doses (rare); not appropriate for Wilson's disease |
| Drug interactions | Corticosteroids blunt effect; largely unstudied otherwise | Unknown in humans; theoretical interactions with anticoagulants | Interacts with ascorbic acid (vitamin C) — separate topical use; chelators can disrupt copper complex |
| WADA status | Banned S0 (2022) | Banned S2 (2011, as actin-regulating peptide) | Not listed |
| Purity risk | Grey-market variability; seek COA ≥98% | Grey-market variability; seek COA ≥98% | Grey-market variability; injectable less standardized than topical cosmetic grades |
BPC-157 — FDA Category 2 bulk drug substance; not compoundable under 503A or 503B as of April 2026. HHS Secretary RFK Jr.'s February 2026 announcement indicated intent to reclassify roughly 14 of the 19 Category 2 peptides (BPC-157 among them), but formal FDA update and Pharmacy Compounding Advisory Committee review are not complete.
TB-500 / Thymosin β-4 — FDA Category 2. Investigational drug under regenRx, Lee's Pharmaceutical, and others for specific indications (dry eye RGN-259, pressure ulcers, EB). Not currently available through US compounding pharmacies.
GHK-Cu — Not on FDA Category 2 list. GRAS as a cosmetic ingredient in topical products (creams, serums, copper peptide solutions). Injectable GHK-Cu is not FDA-approved for any clinical indication and is distributed through research-chemical channels.
All three are banned or restricted under WADA for competitive athletes with the exception of GHK-Cu, which is unlisted at this time.
All three compounds are research-only in the United States. None are FDA-approved for human use in tissue repair. They are available through research suppliers for laboratory research purposes only. Availability and pricing estimates as of April 2026 — actual costs vary by vendor, purity, and quantity. Kalios does not sell compounds and does not facilitate purchase.
BPC-157 — Typically sold by research suppliers as 5 mg or 10 mg lyophilized vials. The most widely stocked of the three, with broad vendor availability and the largest user community. Research-supplier ranges compress meaningfully at higher quantities. Third-party HPLC Certificate of Analysis showing ≥ 98% purity plus mass-spectrometry confirmation of the 15-amino-acid sequence is the practical floor.
TB-500 — Typically sold as 2 mg, 5 mg, or 10 mg lyophilized vials. A recurring quality concern is that some research suppliers sell a partial-sequence "active fragment 17-23" labelled as "TB-500" although the fragment is not full-length 43-amino-acid thymosin β-4. Confirm full-length sequence on the COA; the molecular-weight line (4,963 Da) is the quick tell.
GHK-Cu — Dual supply chain. Topical cosmetic-grade GHK-Cu (creams, serums, copper-peptide solutions typically at 1–3%) is regulated in the US as a cosmetic ingredient and is widely available through dermatology, cosmeceutical, and aesthetic brands — this is a separate, FDA-permitted market from the research-only injectable. Injectable GHK-Cu is sold through the same research-supplier channel as BPC-157 and TB-500, typically as 50 mg or 100 mg lyophilized vials. Expect a pale blue colour on reconstitution from the copper complex — that is the expected appearance, not contamination.
For sourcing, verification, and regulatory considerations specific to each compound, see the individual profiles: BPC-157, TB-500, GHK-Cu.
Kalios does not sell compounds. Pricing and availability vary widely by provider and jurisdiction.
Yes — if the goal maps cleanly onto one mechanism. A single tendon or ligament injury is often handled with BPC-157 alone. Skin rejuvenation, photoageing, hair, and post-procedure recovery are often handled with GHK-Cu alone (topical or injectable). Diffuse, chronic, or systemic soft-tissue damage is often handled with TB-500 alone. The three-way stack makes sense when goals span multiple mechanisms simultaneously — acute repair plus long-horizon remodeling, for example, or post-surgical recovery where all three repair phases are active at once.
For first-time users, BPC-157 is usually the entry point. It has the largest community literature, the most specific dosing guidance, the lowest injection volume (typically 250–500 mcg daily SubQ), and the fewest initial side effects. Add TB-500 if the injury is diffuse, stalled, or has failed to respond to BPC-157 alone. Add GHK-Cu when the goal extends beyond pure injury repair into skin, collagen, hair, or general anti-inflammaging — topical-only GHK-Cu is a reasonable starting point before any injectable use.
Oral BPC-157 has a legitimate rationale — the compound is derived from a gastric-juice protein and has demonstrated gut-stable bioactivity in rodent models of intestinal injury and colitis. For gut-specific applications (IBD, gastric lesions, SIBO), oral is often used. For systemic or tendon/ligament applications, injectable remains the better-characterised route. Oral TB-500 lacks supporting evidence — thymosin β-4 is a 43-amino-acid, ~5,000 Da peptide with poor oral bioavailability; every completed human trial has been injectable or topical. Oral GHK delivered via food-derived peptide supplements has modest cosmetic evidence (Nestor 2015, oral glycine peptide) but does not substitute for topical or injectable GHK-Cu in established protocols.
Yes. All three are small water-soluble peptides without known pairwise interactions in solution, and they are already sold pre-mixed as the Wolverine (BPC-157 + TB-500) and GLOW (GHK-Cu + BPC-157 + TB-500) stacks. The Can They Be Mixed in One Syringe? section above covers the two practical approaches — single-vial co-reconstitution versus sequential draw from separate vials. The combined solution will be pale blue whenever GHK-Cu is present, which is expected.
Community practice is roughly 4–8 weeks on / 2–4 weeks off for BPC-157 and TB-500; GHK-Cu often tolerates longer continuous runs (4–8 weeks on, 1–2 off). The rationale for cycling is to prevent receptor or pathway desensitization, to allow a mechanistic reset, and to monitor lab markers (CBC, CMP, any compound-specific markers) during the off-period. No published randomised trial has formally compared cycling schedules against continuous dosing, so this is an empirical framework rather than a prescribed one. For GHK-Cu topical use, continuous daily use is the norm.
Timelines vary by indication and individual, so these are anecdotal windows rather than guarantees. BPC-157: users often report injury pain reduction within 2–7 days, with structural tissue healing playing out over 3–6 weeks. TB-500: a transient lethargic or flu-like phase is common during the first 1–2 weeks of loading, followed by benefit emerging over 4–6 weeks. GHK-Cu: visible skin-texture and fine-line effects are typically reported at 4–8 weeks topically; injectable systemic effects on hair density and general recovery often take 2–3 full cycles (3–6 months) before being clearly assessable. None of these timelines are FDA-approved claims — they reflect community observation and open-label trial reports.
Last updated: April 2026 | Profile authored by Kalios Peptides research team